| HOME >> MEDICINE >> TECHNOLOGY |
$
764$
436
$
411$ 1,170
$ 1,175Pacemaker systems216
246220
194436
440Total CRM products$
950$ 1,010$
56$
5$ 1,606$ 1,615in millionsU.S.InternationalWorldwideYTD 2011YTD 2010YTD 2011YTD 2010YTD 2011YTD 2010Drug-eluting stent systems$
583
$
8$
571
$
542$ 1,154
$ 1,160Bare-metal stent systems24
3562
6786
102Total coronary stent systems$
7$
53$
33$
9$ 1,240$ 1,262BOSTON SCIENTIFIC CORPORATIONSUPPLEMENTAL NON-GAAP RECONCILIATIONS, CONT.
(Unaudited)Q4 and Full Year 2011 EPS GuidanceQ4 2011 EstimateFull Year 2011 Estimate(Low)(High)(Low)(High)GAAP results$ 0.05$ 0.11$ 0.27$ 0.33Goodwill impairment charge0.45
0.45Other intangible asset impairment charges0.01
0.01Estimated acquisition-related net charges (credits)
0.01
0.000.00
(0.01)Estimated divestiture-related net charges (credits)
0.00
(0.01)(0.35)
(0.36)Estimated restructuring-related charges
0.02
0.010.07
0.06Discrete tax items(0.01)
(0.01)Estimated amortization expense
0.05
0.050.23
0.23Adjusted results$ 0.13$ 0.16$ 0.67$ 0.70An explanation of the Company's use of these non-GAAP measures is provided at the end of this document.
Use of Non-GAAP Financial MeasuresTo supplement Boston Scientific's consolidated financial statements presented on a GAAP basis, the Company discloses certain non-GAAP financial measures, including adjusted net income and adjusted net income per share that exclude certain amounts and regional and divisional revenue growth rates that exclude the impact of changes in foreign currency exchange rates. These non-GAAP financial measures are not in accordance with generally accepted accounting pr
'/>"/>
| SOURCE Boston Scientific Corporation Copyright©2010 PR Newswire. All rights reserved |